1.Meirik O, Fraser IS, d’Arcangues C. Implantable contraceptives for women. Human Reproduction Update. 2003;9(1):49–59.
2.Jacobstein R, Stanley H. Contraceptive implants: providing better choice to meet growing family planning demand. Global Health: Science and Practice. 2013;1(1):11–7.
3.Bahamondes L, Bahamondes MV. New and emerging contraceptives: a state-of-the-art review. International journal of women’s health. 2014;6:221.
4.The RESPOND Project. Hormonal implant services: Delivering a highly effective contraceptive method now available at reduced cost. RESPOND Technical Brief No. 2. September. New York: EngenderHealth (The RESPOND Project). 2013.
5.Ramchandran D, Upadhyay UD. Implants: The next generation. Population reports Series K: Injectables and implants. 2007(7):1–19.
6.Jacobstein R. Hormonal implant services. Delivering a highly effective contraceptive method now available at reduced cost. 2013.
7.Croxatto H, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon®: An overview of the data. Contraception. 1998;58(6):91S–7S.
8.Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertility and sterility. 2009;91(5):1646–53.
9.Alkema L, Kantorova V, Menozzi C, Biddlecom A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. The Lancet. 2013;381(9878):1642–52.
10.Organization WH. Annual technical report: 2013: department of reproductive health and research, including UNDP/UNFPA/WHO/World Bank Special Programme of Research Training in Human Reproduction (HRP). World Health Organization, 2014.
11.Staveteig S, Mallick L, Winter R. Uptake and discontinuation of long-acting reversible contraceptives (LARCS) in low-income countries. 2015.
12.Asnake M, Henry EG, Tilahun Y, Oliveras E. Addressing unmet need for long‐acting family planning in Ethiopia: Uptake of single‐rod progestogen contraceptive implants (Implanon) and characteristics of users. International Journal of Gynecology & Obstetrics. 2013;123:e29-e32.
13.Central Statistical Agency (CSA) [Ethiopia] and ICF. Ethiopia Demographic and Health Survey 2016. Addis Ababa, Ethiopia, and Rockville, Maryland, USA: CSA and ICF. 2016.
14.Birhane K, Hagos S, Fantahun M. Early discontinuation of implanon and its associated factors among women who ever used implanon in Ofla District, Tigray, Northern Ethiopia. International Journal of Pharma Sciences and Research. 2015;6(3):544–51.
15.Siyoum M, Mulaw Z, Abuhay M, Kebebe H. Implanon Discontinuation Rate and Associated Factors among Women who ever Used Implanon in the Last Three Years in Debre Markos Town, Northwest Ethiopia, 2016, Cross Sectional Study. ARC Journal of Public Health and Community of Medicine. 2017;2:8–16.
16.Bradley SE, Polis CB, Bankole A, Croft T. Global Contraceptive Failure Rates: Who Is Most at Risk? Studies in family planning. 2019.
17.Curtis S, Evens E and Sambisa W. Contraceptive Discontinuation and Unintended Pregnancy: An Imperfect Relationship. International Perspectives on Sexual and Reproductive Health. 2011; 37(2):58–66.
18.Puri M, Henderson JT, Harper CC, Blum M, Joshi D, Rocca CH. Contraceptive discontinuation and pregnancy postabortion in Nepal: a longitudinal cohort study. Contraception. 2015;91(4):301–7.
19.Birhane K, HagoS S, Fantahun M. Earlydiscontinuation of implanon and its associated factors among women who ever used implanon in Ofla District, Tigray, Northern Ethiopia. International Journal of Pharma Sciences and Research (IJPSR). Mar 2015; Vol. 6: No.3.
20.Modey EJ, Aryeetey R, Adanu R. Contraceptive discontinuation and switching among Ghanaian women: evidence from the Ghana Demographic and Health Survey, 2008. African journal of reproductive health. 2014;18(1):84–92.
21.Asmah Mastor SLK, Siti Zawiah Omar. Users’ perspectives on Implanon in Malaysia, a multicultural Asian country. Open Access Journal of Contraception 2011;2:79–84.
22.Madugu N. H., Abdul M. A., Bawa, U. and Kolawole, B. Uptake of Hormonal Implants Contraceptive in Zaria, Northern Nigeria. Open Journal of Obstetrics and Gynecology. 2015; 5: 268–273..
23.Balogun O. R. ONAAS, and. Fawole A. A. Implanon sub-dermal implant: an emerging method of contracep-tion in Ilorin, Nigeria. Journal of Medical and Biomedical Sciences 2014;3(1):1–5.
24.Burusie A. Reasons for premature removal of Implanon among users in Arsi zone, Oromia region, Ethiopia, 2013. Reprod Syst Sex Disord. 2015;4(148):2.
25.Pam V, Mutihir J, Karshima J, Kahansim M, Musa J, Daru P. Factors associated with use and discontinuation of implanon contraceptive in Jos, Nigeria. Tropical Journal of Obstetrics and Gynaecology. 2014;31(2):90–9.
26.Marston C, Cleland J. Relationships between contraception and abortion: a review of the evidence. International family planning perspectives. 2003:6–13.
27.Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM. Continuation of reversible contraception in teenagers and young women. Obstetrics and gynecology. 2012;120(6):1298.
28.Black KI, Bateson D, Harvey C. Australian women need increased access to long-acting reversible contraception. Med J Aust. 2013;199(5):317–8.
29.Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstetrics and gynecology. 2011;117(5):1105.
30.Tadesse A, Kondale M, Agedew E, Gebremeskel F, Boti N, Oumer B. Determinant of Implanon discontinuation among women who ever used Implanon in Diguna Fango District, Wolayita zone, southern Ethiopia: a community based case control study. International journal of reproductive medicine. 2017;2017.